The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Cancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., Schafer, Z. T., Evans, R. M., Suda, T., Lee, C.-H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2882 · Cited by 729
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8154 · Cited by 551
Matsumoto, A., Masuhara, M., Mitsui, K., Yokouchi, M., Ohtsubo, M., Misawa, H., Miyajima, A., & Yoshimura, A. (1997) · Blood · doi:10.1182/blood.v89.9.3148 · Cited by 528
Hu, C.-J., Sataur, A., Wang, L., Chen, H., & Simon, M. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0419 · Cited by 355
Jørgensen, H. G., Allan, E. K., Jordanides, N. E., Mountford, J. C., & Holyoake, T. L. (2007) · Blood · doi:10.1182/blood-2006-11-057521 · Cited by 306
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Chen, Y., Hu, Y., Zhang, H., Peng, C., & Li, S. (2009) · Nature Genetics · doi:10.1038/ng.389 · Cited by 293
Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia
Hoelbl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoelzl, M. A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000062 · Cited by 239
Nègre, D., Mangeot, P.-E., Duisit, G., Blanchard, S., Vidalain, P.-O., Leissner, P., Winter, A.-J., Rabourdin-Combe, C., Mehtali, M., Moullier, P., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301292 · Cited by 206
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation
Kieslinger, M., Woldman, I., Moriggl, R., Hofmann, J., Marine, J.-C., Ihle, J. N., Beug, H., & Decker, T. (2000) · Genes & Development · doi:10.1101/gad.14.2.232 · Cited by 185
Activation of Stress Response Gene SIRT1 by BCR-ABL Promotes Leukemogenesis
Yuan, H., Wang, Z., Li, L., Zhang, H., Modi, H., Horne, D., Bhatia, R., & Chen, W. (2012) · Blood · doi:10.1182/blood-2011-06-361691 · Cited by 182
Wang, Z., Li, G., Tse, W., & Bunting, K. D. (2009) · Blood · doi:10.1182/blood-2008-09-181107 · Cited by 134
Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells
Kominsky, D. J., Klawitter, J., Brown, J. L., Boros, L. G., Melo, J. V., Eckhardt, S. G., & Serkova, N. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3291 · Cited by 121
Chomel, J., & Turhan, A. G. (2011) · Oncotarget · doi:10.18632/oncotarget.333 · Cited by 96
Berria, R., Glass, L. C., Mahankali, A., Miyazaki, Y., Monroy, A., Filippis, E. D., Cusi, K. J., Cersósimo, E., DeFronzo, R. A., & Gastaldelli, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100146 · Cited by 91
Repression of β-catenin signaling by PPARγ ligands
Lu, D., & Carson, D. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.010 · Cited by 86
Roth, O., Spreux‐Varoquaux, O., Bouchet, S., Rousselot, P. H., Castaigné, S., Rigaudeau, S., Raggueneau, V., Thérond, P., Devillier, P., Molimard, M., et al. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.10.007 · Cited by 84
Self-citationIdentification of HIF2α as an important STAT5 target gene in human hematopoietic stem cells
Fátrai, S., Wierenga, A. T. J., Daenen, S. M. G. J., Vellenga, E., & Schuringa, J. J. (2011) · Blood · doi:10.1182/blood-2010-08-303669 · Cited by 79
Liu, S., Walker, S. R., Nelson, E. A., Cerulli, R. A., Xiang, M. H., Toniolo, P. A., Qi, J., Stone, R. M., Wadleigh, M., Bradner, J. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0341 · Cited by 73
Du, J., Chen, Y., Li, Q., Han, X., Cheng, C., Wang, Z., Danielpour, D., Dunwoodie, S. L., Bunting, K. D., & Yang, Y. (2012) · Blood · doi:10.1182/blood-2011-10-387902 · Cited by 71
Prost, S., Dantec, M. L., Augé, S., Grand, R. L., Derdouch, S., Aurégan, G., Déglon, N., Relouzat, F., Aubertin, A.-M., Maillère, B., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33037 · Cited by 67
Self-citationSzántó, A., & Nagy, L. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006445 · Cited by 63
Cited2 is required for normal hematopoiesis in the murine fetal liver
Chen, Y., Haviernik, P., Bunting, K. D., & Yang, Y. (2007) · Blood · doi:10.1182/blood-2007-01-066316 · Cited by 62
Troglitazone reverses the multiple drug resistance phenotype in cancer cells
Harkness (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3314 · Cited by 31
Wang, L., Giannoudis, A., Austin, G. M., & Clark, R. E. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.05.013 · Cited by 19
Cited2 in hematopoietic stem cell function
Du, J., & Yang, Y. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283606022 · Cited by 19
IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
Pitulis, N., Papageorgiou, E. G., Τέντα, Ρ., Lembessis, P., & Koutsilieris, M. (2009) · PubMed · Cited by 14
Avagyan, S., Aguiló, F., Kamezaki, K., & Snoeck, H. (2011) · Blood · doi:10.1182/blood-2011-07-365080 · Cited by 12
Mouse models as tools to understand and study BCR-ABL1 diseases.
Koschmieder, S., & Schemionek, M. (2011) · PubMed · Cited by 11
Cited by
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 374
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Metadata
- Authors
- Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., Saliba, J., Massonnet, G., Beressi, J.-P., Verhoeyen, E., Raggueneau, V., Maneglier, B., Castaigne, S., Chomienne, C., Chrétien, S., Rousselot, P., & Leboulch, P.
- Venue
- Nature
- Published
- 2015-09
- Volume
- 525
- Issue
- 7569
- Pages
- 380-383
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2122113546
- Cited by
- 272
- References
- 35
- FWCI
- 25.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.